Date: 2013-10-15
Type of information: Collaboration agreement
Compound: antibody drug conjugates (ADCs)
Company: PolyTherics (UK) TUBE Pharma (Austria)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
R&D
Action mechanism:
Disease:
Details: * On October 15, 2013, PolyTherics Limited and TUBE Pharma have announced that they are collaborating to produce reagents to link novel cytotoxic drugs developed by TUBE to antibodies using PolyTherics’ proprietary ThioBridge™ conjugation technology for the production of better antibody drug conjugates (ADCs). TUBE has developed a series of proprietary synthetic tubulin-binding agents, referred to as cytolysins, which have been shown to be effective against a range of cancer cell lines, including drug-resistant cancer cells. Cytolysins rapidly trigger cell death and, conjugated to small molecules, polymers, proteins and peptides, they have shown significant efficacy in preclinical models of cancer. PolyTherics has developed ThioBridge™, a site-specific conjugation technology, to attach cytotoxic payloads to whole antibodies, antibody fragments and other scaffolds. ThioBridge™ enables the production of ADCs with reduced heterogeneity and very good stability compared with alternative conjugation methods.
PolyTherics and TUBE can undertake feasibility studies for companies interested in evaluating ThioBridge™ with a cytolysin payload or the ThioBridge™-cytolysin reagent can be supplied for companies to evaluate in-house.
Financial terms:
Latest news:
